期刊文献+

血浆中卵巢癌相关蛋白质的筛选 被引量:2

Screening of Ovarian Cancer Related Proteins in Plasma
下载PDF
导出
摘要 目的:应用液体蛋白芯片飞行时间质谱系统分析卵巢癌的血浆蛋白质表达谱,寻找具有潜在诊断意义的血浆肿瘤标志物,以利于卵巢癌的早期诊断。方法:收集卵巢浆液性癌30例、卵巢浆液性瘤18例、妇科良性疾病(包括卵巢囊肿和子宫肌瘤)30例的血浆样本,经磁珠纯化、基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)分析及ClinproTools生物信息学方法研究其血浆蛋白表达谱。结果:在卵巢癌组和非癌组间,得到差异性蛋白48个(P<0.05),用其中四个联合分组能力最强的蛋白质4 210.91(m/z),4 470.17(m/z),2 210.9(m/z),1866.88(m/z)建立了诊断模型,癌组和非癌组的识别率为100%。结论:利用液体芯片-飞行质谱技术进行血浆卵巢癌相关蛋白质的研究,得到了差异蛋白和诊断模型,对卵巢癌的诊断具有潜在价值。 Objective: To screen ovarian cancer-related proteins in plasma by liquid chip - MALDI-TOF Mass Spectrometry and to seek potential biomarkers of ovarian cancer for early diagnosis. Methods: The plasma protein profiling of one group of 30 patients with ovarian serous adenocarcimoma, one group of 18 patients with ovarian serous cystadenoma and one group of 30 patients with myoma of uterus or simple ovarian csyts were analyzed by the ClinProt system ( including functional magnetic bead, MALDI-TOF-MS technology and bio-information software). Results: The plasma protein of the group of ovarian serous adenocarcimoma and non-cancer group ( the other two groups) were compared and got 48 differential proteins. We established the diagnostic model of ovarian cancer using 4 proteins, 4 210. 91 ( m/z), 4 470. 17 (m/z), 2 210. 9 (m/z), 1 866. 88 (m/z) respectively. The recognition rate of cancer group and non-cancer group were both 100%. Conclusion: The differential proteins and diagnostic model were got by liquid chip- MALDI-TOF Mass Spectrometry after the comparison of cancer' s and non-cancer' s plasma spectrum. These proteins may have potential diagnosis value of ovarian cancer.
出处 《肿瘤预防与治疗》 2010年第4期274-279,共6页 Journal of Cancer Control And Treatment
基金 国家自然科学基金资助 项目批准号:30471807
关键词 卵巢肿瘤 液体蛋白芯片飞行质谱 蛋白质谱 早期诊断 Ovarian Neoplasms ClinProt System Proteomic Profiling Early Diagnosis
  • 相关文献

参考文献10

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
  • 2王静,张小为,袁杨,郭红燕,熊光武,于中连,张健,胡晓慧,殷汝雷.应用液体蛋白芯片飞行时间质谱系统研究卵巢癌的血清蛋白表达谱[J].现代妇产科进展,2008,17(2):88-91. 被引量:6
  • 3Freed GL,Cazares LH,Fichandler CE,et al.Differential capture of serum proteins for expression profiling and biomarker discovery in pre-and posttreatment head and neck cancer samples[J].Laryngoscope,2008,118(1):61-68.
  • 4Josep V,John P,Paul T,et al.Serum peptide profiling by magnetic particle-assisted,automated sample processing and MALDI-TOF mass spectrometry[J].Anal Chem,2004,76:1560-1570.
  • 5Martorella A,Robbins R.Serum peptide profiling:identifying novel cancer biomarkers for early disease detection[J].Acta Biomed,2007,78(Suppl 1):123-128.
  • 6Cheng AJ,Chen LC,Chien,KY,et al.Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology[J].Clin Chem,2005,51:2236-2244.
  • 7王雅杰,方芳,周亚莉,张国军,吕虹,刘志忠,史从宁,耿会娟,韩金利,康熙雄.血清中胶质瘤疾病相关蛋白质的筛选[J].中国实验诊断学,2008,12(5):619-624. 被引量:3
  • 8王静,张小为.血清和血浆中血栓蛋白差异的研究[J].诊断学理论与实践,2007,6(4):323-326. 被引量:3
  • 9Zhu Y,Wu R,Sangha N,et al.Classifications of ovarian cancer tissues by proteomic patterns[J].Proteomics,2006,6(21):5846-5856.
  • 10Wang J,Zhang X,Ge X,et al.Proteomic studies of early-stage and advanced ovarian cancer patients[J].Gynecol Oncol,2008,111(1):111-119.

二级参考文献20

  • 1贺石林,葛金文.正确选择血标本的思考[J].诊断学理论与实践,2005,4(6):433-434. 被引量:7
  • 2贺石林,葛金文.凝血与临床检验中血标本的选择[J].诊断学理论与实践,2005,4(6):513-516. 被引量:8
  • 3张雪群,姜颖,厉有名,贺福初.人血浆低丰度蛋白富集方法的研究进展[J].中华检验医学杂志,2006,29(10):947-950. 被引量:9
  • 4[1]Rudstein-Svetlicky N,Loewenthal R,Horejsi V,et al.HLA-G levels in serum and plasma[J].Tissue Antigens,2007,69(Suppl 10):140-142.
  • 5[2]Wu CY,Wu MS,Chiang EP,et al.Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution[J].Clin Cancer Res,2007,13(7):2054-2060.
  • 6[4]Thadikkaran L,Siegenthaler MA,Crettaz D,et al.Recent advances in blood-related proteomics[J].Proteomics,2005,5(12):3019-3034.
  • 7[5]Omenn GS,States DJ,Adamski M,et al.Overview of the HUPO Plasma Proteome Project:results from the pilot phase with 35 collaborating laboratories and multiple analytical groups,generating a core dataset of 3020 proteins and a publicly-available database[J].Proteomics,2005,5(13):3226-3245.
  • 8Jemal A, Thomas A, Murray T, et al. Cancer Statistics [J]. CA Cancer J Clin,2002,52:23-47.
  • 9Cheng A J, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology [ J ]. Clin Chem, 2005,51 : 2236- 2244.
  • 10Zhang X,Leung SM,Morris CR,et al. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma [ J ]. J Biomol Tech,2004,15 : 167-175.

共引文献8

同被引文献31

  • 1吴化平,颉彦华,赵其景,秦英.卵巢癌对顺铂耐药机制的研究进展[J].中国肿瘤临床,2006,33(21):1256-1259. 被引量:12
  • 2Onda T, Kobayashi H, Nakanishi T, et al. Feasilility study of neoadjuvant chemotherapy followed by interval debu|king surgery for stage I11/IV ovarian.tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206[J]. Gynecol Oncol, 2009,113:57-62.
  • 3Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer [J]. MethodH Mol Biol, 2009,472:413-437.
  • 4Bristow Re, Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen Gynecol [J]. Oncol, 2009,112(1): 1-3.
  • 5Kuhn W, Rutke S, Sppathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survial for patients with poor prog-nosis in intemation federation of gynecology and obstetrics stage III ovarian carcinoma[J]. Cancer, 2008,92(10):2585-2591.
  • 6A.Jemal, R.Siegel, J.Xu, E.Wrd, cancer statistics, 2010 [J]. CA Cancer J Clin, 2010,60:277-300.
  • 7S.Dutta, FQ.Wang, A.Phalen, D.A.Fishman,Biomrkers for ovarian cancer detection and therapy[J]. Cancer Biol Tiler, 2010,9:668-677.
  • 8Vergoteg I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer [J]. N Engl J Med, 2010,363(10):943-953.
  • 9McLean Ka, Shah Ca, Thompson Sa, et al. Ovarian cancer in the elderly: outcomes with neoadj uvant chemotherapy or primary cytoreduction[J]. Gyneeol Oneol, 2010,118(1):43-46.
  • 10Weinberg Le, Rod riguezG, H urteau JA, et al. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer[J]. J Surg Oncol, 2010, 101(4) : 334-343.

引证文献2

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部